1. Home
  2. RENX vs XRTX Comparison

RENX vs XRTX Comparison

Compare RENX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$1.78

Market Cap

4.1M

Sector

N/A

ML Signal

N/A

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$2.09

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RENX
XRTX
Founded
2021
2011
Country
United States
Canada
Employees
38
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
4.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
RENX
XRTX
Price
$1.78
$2.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
220.4K
21.7K
Earning Date
05-22-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.35
52 Week High
$3.48
$3.60

Technical Indicators

Market Signals
Indicator
RENX
XRTX
Relative Strength Index (RSI) 49.06 42.23
Support Level $1.76 $2.03
Resistance Level $1.82 $3.03
Average True Range (ATR) 0.13 0.16
MACD 0.03 -0.02
Stochastic Oscillator 45.24 22.64

Price Performance

Historical Comparison
RENX
XRTX

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Share on Social Networks: